Article

Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists

Department of Pathology, Griffith Medical School, Gold Coast Campus, Gold Coast, Queensland 4222, Australia.
Postgraduate medical journal (Impact Factor: 1.55). 03/2008; 84(988):78-82. DOI: 10.1136/pgmj.2007.064881
Source: PubMed

ABSTRACT The follicular variant of papillary thyroid carcinoma (FVPTC) presents a type of papillary thyroid cancer that has created continuous diagnosis and treatment controversies among clinicians and pathologists. In this review, we describe the nomenclature, the clinical features, diagnostic problems and the molecular biology of FVPTC. It is important for clinicians to understand this entity as the diagnosis and management of this group of patient may be different from other patients with conventional PTC. The literature suggests that FVPTC behaves in a way similar, clinically, to conventional papillary thyroid carcinoma. However, there are some genotypic differences which may characterise this neoplasm. These parameters may account for the phenotypic variation described by some scientists in this type of cancer. Further understanding can only be achieved by defining strict pathological criteria, in-depth study of the molecular biology and long term follow-up of the optional patients with FVPTC.

Download full-text

Full-text

Available from: Alfred K Y Lam, Jul 07, 2015
0 Followers
 · 
184 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutation of the BRAF gene is common in thyroid cancer. Follicular variant of papillary thyroid carcinoma is a variant of papillary thyroid carcinoma that has created continuous diagnostic controversies among pathologists. The aims of this study are to (1) investigate whether follicular variant of papillary thyroid carcinoma has a different pattern of BRAF mutation than conventional papillary thyroid carcinoma in a large cohort of patients with typical features of follicular variant of papillary thyroid carcinoma and (2) to study the relationship of clinicopathological features of papillary thyroid carcinomas with BRAF mutation. Tissue blocks from 76 patients with diagnostic features of papillary thyroid carcinomas (40 with conventional type and 36 with follicular variant) were included in the study. From these, DNA was extracted and BRAF V600E mutations were detected by polymerase chain reaction followed by restriction enzyme digestion and sequencing of exon 15. Analysis of the data indicated that BRAF V600E mutation is significantly more common in conventional papillary thyroid carcinoma (58% versus 31%, P = .022). Furthermore, the mutation was often noted in female patients (P = .017), in high-stage cancers (P = .034), and in tumors with mild lymphocytic thyroiditis (P = .006). We concluded that follicular variant of papillary thyroid carcinoma differs from conventional papillary thyroid carcinoma in the rate of BRAF mutation. The results of this study add further information indicating that mutations in BRAF play a role in thyroid cancer development and progression.
    Human pathology 12/2010; 42(4):500-6. DOI:10.1016/j.humpath.2009.09.023 · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment with thyroid hormone is needed in patients with differentiated thyroid carcinoma (DTC) after the initial treatment (thyroidectomy followed, in most cases, by radioiodine remnant ablation) for two reasons: a) Correction of hypothyroidism in an athyreotic patient (replacement therapy); b) Blockade of thyrotropin (TSH) secretion in view of the TSH-dependence of DTC (TSH-suppressive therapy). Levothyroxine (L-T4) is the hormone of choice, since combina-tion with levotriiodothyronine does not add any clear advantage with respect to L-T4 monotherapy. While replacement therapy obviously is a lifelong requirement, duration of TSH-suppressive therapy depends on the tumor risk stratification after and the response to the initial treatment. According to recent European and American guidelines, in low-risk DTC L-T4 treatment should be carried out at TSH-suppressive doses until there is evidence that the patient is disease-free. In high-risk DTC, TSH suppression should be maintained for several years after such an evidence has been achieved. After-wards, the patient can be shifted to replacement doses, also to avoid the risks of iatrogenic thyrotoxicosis, especially in the elderly and/or in the presence of cardiovascular disease. The dose of L-T4 must be invidualized; particular attention must be given to the coexistence of pathophysiological conditions or drug treatments that may affect L-T4 absorption or me-tabolism.
    Current Cancer Therapy Reviews 11/2009; 5:296-302. DOI:10.2174/157339409789712717
  • [Show abstract] [Hide abstract]
    ABSTRACT: Existing variance calculations for spectral estimates are unsatisfactory in that they depend upon information that is usually unavailable in practice. Some recent work in spectral estimation has involved the computation of bounds on the average spectral density in some region from a true correlation matrix. The computation of these bounds involves optimization over a set of spectra that are consistent with the correlation matrix. The specific new work to be reported on involves the construction of confidence regions for the true correlation matrix, based on a Wishart distributed sample correlation matrix. Bounds computed over spectra that are consistent with the true correlation matrix being in this set are valid with a certain minimum a priori probability which does not depend upon unavailable information about the spectrum. The result is a performance characterization for the bounding method which is different and, in some ways, more satisfactory than the existing variance analyses for other spectral estimation methods.
    Acoustics, Speech, and Signal Processing, IEEE International Conference on ICASSP '84.; 04/1984